Day: July 25, 2025

Form 8.3 – [MARLOWE PLC – 24 07 2025] – (CGWL)

Written by Customer Service on July 25, 2025. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION(a) Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree MARLOWE PLC(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e) Date position held/dealing...

ZURZUVAE® (zuranolone) Receives Positive Opinion from CHMP for the Treatment of Women with Postpartum Depression

Written by Customer Service on July 25, 2025. Posted in Public Companies.

CAMBRIDGE, Mass., July 25, 2025 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending marketing authorization for ZURZUVAE® (zuranolone) for the treatment of postpartum depression (PPD) in adults following childbirth. If approved by the European Commission (EC), ZURZUVAE will be the first treatment authorized within the European Union specifically indicated to treat depressive symptoms for women with PPD. ZURZUVAE is a once-daily, oral, 14-day treatment which was approved by the U.S. Food and Drug Administration (FDA) in 2023. “This is an important milestone for maternal health in the European Union,” said Priya Singhal, M.D., M.P.H., Head of Development at Biogen. “ZURZUVAE represents a novel...

Valeura Energy Inc.: Strategic Farm-in Agreement with PTTEP

Written by Customer Service on July 25, 2025. Posted in Public Companies.

Major Offshore Acreage Expansion Creates New Growth Platform in the Gulf of ThailandSINGAPORE, July 25, 2025 (GLOBE NEWSWIRE) — Valeura Energy Inc. (TSX:VLE, OTCQX:VLERF) (“Valeura” or the “Company”) is pleased to announce that it has entered into a Farm-in Agreement with PTT Exploration and Production Plc (“PTTEP”), through its subsidiary, PTTEP Energy Development Company Limited to earn a 40% interest in Blocks G1/65 and G3/65 (the “Blocks”), in the offshore Gulf of Thailand (the “Farm-in”). Key HighlightsStrategic Partnership: Farm-in Agreement with PTTEP, the largest oil and gas explorer, producer, and operator in Thailand; Substantial Acreage Expansion: Increases Valeura’s gross acreage position in Thailand from 2,623 km² to 22,757 km²; Prime Location Adjacent...

Gencor Releases Second Quarter Fiscal 2025 Results

Written by Customer Service on July 25, 2025. Posted in Earnings Releases And Operating Results.

ORLANDO, Fla., July 25, 2025 (GLOBE NEWSWIRE) — Gencor Industries, Inc. (the “Company” or “Gencor”) (NYSE American: GENC) announced today net revenue for the quarter ended March 31, 2025 of $38,204,000 decreased 6.1% from net revenue for the quarter ended March 31, 2024 of $40,676,000. Revenue from contract equipment sales recognized at a point in time decreased slightly in the quarter ended March 31, 2025. As a percent of sales, gross profit margins were 29.7% in the quarter ended March 31, 2025, compared to 30.3% in the quarter ended March 31, 2024 due to a marginally higher material costs. Product engineering and development expenses decreased $212,000 to $681,000 for the quarter ended March 31, 2025, as compared to $893,000 for the quarter ended March 31, 2024, due to reduced headcount. Selling, general and administrative (“SG&A”)...

Gencor Releases First Quarter Fiscal 2025 Results

Written by Customer Service on July 25, 2025. Posted in Earnings Releases And Operating Results.

ORLANDO, Fla., July 25, 2025 (GLOBE NEWSWIRE) — Gencor Industries, Inc. (the “Company” or “Gencor”) (NYSE American: GENC) announced today net revenue for the quarter ended December 31, 2024 of $31,416,000 increased 20.7% over net revenue for the quarter ended December 31, 2023 of $26,018,000. Revenue from contract equipment sales recognized over time increased significantly and was slightly offset by a decrease in parts sales. As a percent of sales, gross profit margins were 27.6% in the quarter ended December 31, 2024, compared to 29.0% in the quarter ended December 31, 2023 due to a smaller contribution of parts sales to total sales in the quarter ended December 31, 2024. Product engineering and development expenses decreased $124,000 to $677,000 for the quarter ended December 31, 2024, as compared to $801,000 for the quarter...

Wabash Announces Second Quarter 2025 Results

Written by Customer Service on July 25, 2025. Posted in Earnings Releases And Operating Results.

Quarterly revenue of $459 million – beating midpoint of outlook range on modestly stronger than expected shipments. Parts & Services generated positive revenue growth sequentially and year-over-year. GAAP operating loss of $5 million or Non-GAAP adjusted operating loss of $0.1 million; Excludes impact of $5 million in expenses associated with the legal verdict. Quarterly GAAP EPS of $(0.23) or Non-GAAP adjusted EPS of $(0.15). Beating Expectations due to slightly higher revenue and cost containment actions throughout the quarter. Total backlog of $1.0 billion ending Q2; Market environment continues to be challenging as economic concerns and uncertainty remain. 2025 revenue outlook reduced to $1.6B, Non-GAAP adjusted EPS outlook reduced to $(1.15), excluding impact in connection with the legal verdict.LAFAYETTE, Ind., July...

Lakeland Financial Reports Record Second Quarter Performance; Net Income Grows by 20% to $27.0 Million, as Net Interest Income Expands by 14%

Written by Customer Service on July 25, 2025. Posted in Public Companies.

WARSAW, Ind., July 25, 2025 (GLOBE NEWSWIRE) — Lakeland Financial Corporation (Nasdaq Global Select/LKFN), parent company of Lake City Bank, today reported record second quarter net income of $27.0 million for the three months ended June 30, 2025, which represents an increase of $4.4 million, or 20%, compared with net income of $22.5 million for the three months ended June 30, 2024. Diluted earnings per share were $1.04 for the second quarter of 2025 and increased $0.17, or 20%, compared to $0.87 for the second quarter of 2024. On a linked quarter basis, net income increased $6.9 million, or 34%, from $20.1 million. Diluted earnings per share increased $0.26, or 33%, from $0.78 on a linked quarter basis. Pretax pre-provision earnings, which is a non-GAAP measure, were $35.9 million for the three months ended June 30, 2025, an increase...

European regulatory authority adopts positive opinion for Novo Nordisk’s Alhemo® (concizumab), recommending label expansion to treat haemophilia A and B without inhibitors

Written by Customer Service on July 25, 2025. Posted in Public Companies.

Pending European Commission (EC) approval, Alhemo® will become available to all adult and paediatric patients 12 years and older living with severe haemophilia A and moderate or severe haemophilia B without inhibitors. This positive opinion by the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) is based on results from the explorer8 trial, which showed that Alhemo® reduced spontaneous and traumatic bleeds for patients living with haemophilia A and B without inhibitors compared with no prophylaxis1. If approved by the EC, Alhemo®, with its pen-injector device, has the potential to be an efficacious and easy-to-use option for patients with haemophilia A and B without inhibitors1-3.Bagsværd, Denmark, 25 July 2025 – Novo Nordisk today announced that the European Medicines Agency’s Committee for Medicinal...

W&T Offshore Announces Timing of Second Quarter 2025 Earnings Release and Conference Call

Written by Customer Service on July 25, 2025. Posted in Public Companies.

HOUSTON, July 25, 2025 (GLOBE NEWSWIRE) — W&T Offshore, Inc. (NYSE: WTI) (the “Company”) today announced the timing of its second quarter 2025 earnings release and conference call. The Company said it will issue its second quarter 2025 earnings release on Monday, August 4, 2025, after the close of trading on the NYSE and host a conference call to discuss financial and operational results on Tuesday, August 5, 2025, at 9:00 a.m. Central Time (10:00 a.m. Eastern Time.) Interested parties may participate by dialing (844) 739-3797. International parties may dial (412) 317-5713. Participants should request to be joined to the “W&T Offshore, Inc. Conference Call.” This call will also be webcast and available on W&T Offshore’s website at www.wtoffshore.com under “Investors.” An audio replay will be available on the Company’s...

AirSculpt Technologies Announces Second Quarter Fiscal 2025 Earnings Release Date and Conference Call

Written by Customer Service on July 25, 2025. Posted in Public Companies.

MIAMI BEACH, Fla., July 25, 2025 (GLOBE NEWSWIRE) — AirSculpt Technologies, Inc. (“AirSculpt”) (NASDAQ: AIRS), an industry leader and provider of premium body contouring procedures, today announced it will report second quarter 2025 financial results before market open on Friday, August 1, 2025, to be followed by a conference call on the same day at 8:30 a.m. Eastern Time. The conference call can be accessed by dialing 1-877-407-9716 (toll-free domestic) or 1-201-493-6779 (international) using the conference ID 13754561 or by clicking this link to request a return call for instant telephone access to the event. The live webcast may be accessed via the investor relations section of the AirSculpt Technologies website at https://investors.airsculpt.com. A replay of the webcast will be available for approximately 90 days. About AirSculpt AirSculpt...

Day: July 25, 2025

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals